DIAGNOS

August 28, 2017

Autorité des marchés financiers
British Columbia Securities Commission
Alberta Securities Commission
Manitoba Securities Commission
Ontario Securities Commission
TSX Venture Exchange

Subject : Diagnos Inc. (the « Issuer ») – Restatement of March 31, 2017 annual filings and annual report

Dear Madam / Sir :

This letter is to inform you of the refiling of the Issuer's March 31, 2017 annual filings comprised of the March 31, 2017 restated annual financial statements, restated annual Management Discussion and Analysis (MD&A) as well as the 2017 annual report.

After the initial release, on June 20, 2017, of the Issuer's March 31, 2017 consolidated financial statements, the Issuer determined that the conversion options embedded in the secured convertible debentures and the stock warrants issued during the fiscal years ended March 31, 2016 and March 31, 2017 should have been classified as equity upon initial recognition. The impacts of such adjustments for the year ended March 31, 2017 are reflected in the restated March 31, 2017 consolidated financial statements filed on August 28, 2017.

The Issuer previously reported a comprehensive loss of $5,306,378 and a basic diluted comprehensive loss per share of $0.04 for the year ended March 31, 2017. The restatement resulted in a comprehensive loss of $2,815,282 and a basic diluted comprehensive loss per share of $0.02 for the same year. The variance in comprehensive loss of $2,491,096 is detailed as follows:

	Year ended March 31, 2017
	$
Reversal of change in fair values of conversion options	(2,195,109)
Reversal of change in fair values of warrants	(84,133)
Adjustment to interest expense	(211,854)
	(2,491,096)

The prior period adjustments had no impact on the consolidated statements of loss and comprehensive loss for the year ended March 31, 2016.

For further information, please contact Mr. Marc-André Massue at 450-678-8882 ext. 235.

Yours faithfully,

Marc-André Massue

Marc-André Massue, CFO